WEST CALDWELL, NJ and TORONTO, July 11, 2016 (GlobeNewsire/-) EastGate Biotech Corp. (Pink Sheets: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has announced that CEO Anna Gluskin recently completed an interview with Mr. Everett Jolly from Uptick Newswire.

The interview is now available for review on Uptick’s website:

https://upticknewswire.com/anna-gluskin-ceo-witheastgate-biotech-corp-discusses-their-new-delivery-for-insulin/

 

In the interview link above, Ms. Gluskin addresses the 4 main points that would be considered the most pressing questions to the company and main points the company would like to address to the public:

 

  1.  Innovative insulin Delivery Methods.  Traditional vs. EastGate\s mucosal delivery
  2. Financials and progress from R&D to selling to the retail market
  3. Distributions Channels
  4. The company’s recent agreement with Proactive Solutions

 

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:  Rose Perri 1-647-692-0652
Email:  
information@eastgatepharmaceuticals.com  
Website: 
www.EastGateBiotech.com